SCHEMBL110283

SCHEMBL110283

Nc1cccc(OC(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
ALDH1A1 P00352 3/20 0.54
MAOB P27338 2/20 0.52
MAPT P10636 3/20 0.50
POLB P06746 1/20 0.50
HSP90AA1 P07900 1/20 0.50
TP53 P04637 1/20 0.48
DRD1 P21728 1/20 0.46
CASP1 P29466 1/20 0.46
RECQL P46063 1/20 0.46
MAP4K4 O95819 1/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
APP P05067 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375904 1.00 CYP3A4 (0.54) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL1039181 0.80 ALDH1A1 (0.47) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL23951643 0.80 ALDH1A1 (0.52) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL4639616 0.80 MAOB (0.64) CYP3A4MAOBMAPTTP53APP
SCHEMBL28861196 0.79 MAOB (0.48) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL8365619 0.79 MAOA (0.53) CYP3A4DRD1MAP4K4MEN1
SCHEMBL29368162 0.78 CYP3A4 (0.59) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL4649436 0.78 ALDH1A1 (0.59) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL105230 0.78 CYP3A4 (0.59) CYP3A4ALDH1A1MAOBMAPTPOLB
SCHEMBL18884385 0.78 TAS2R14 (0.51) MAPTPOLBDRD1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398769-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2011-12-28 EP claimed
WO-2010094678-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO claimed
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE, INC. 2010-08-26 US claimed
WO-2010073011-A2 COMPOUNDS USEFUL AS MEDICAMENTS BETAGENON AB (SE) 2010-07-01 WO claimed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US claimed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO claimed
US-7009052-B2 Sulfonamide derivatives WARNER LAMBERT COMPANY LLC (US) 2006-03-07 US claimed
US-20050004367-A1 Sulfonamide derivatives DU DANIEL Y (US) 2005-01-06 US claimed
EP-4688148-A1 SELECTIVE RAPAMYCIN ANALOGS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2026-02-11 EP disclosed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
WO-2025215115-A1 COMPOUNDS FOR USE THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES, PSYCHIATRIC DISORDERS, INFLAMMATION, EPILEPSY AND SEIZURES B&A ONCOMEDICAL (FR) 2025-10-16 WO disclosed
EP-4601744-A1 NEW COMPOUNDS, PROCESSES FOR PREPARING THE SAME AND THEIR USE AS DRUGS B&A Oncomedical (FR) 2025-08-20 EP disclosed
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 US disclosed
US-20030191311-A1 A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease EVOTEC INTERNATIONAL GMBH (DE) 2003-10-09 US disclosed
US-20030187268-A1 Imidazole derivatives EVOTEC INTERNATIONAL GMBH (DE) 2003-10-02 US disclosed
US-6610723-B2 Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration HOFFMANN-LA ROCHE INC. 2003-08-26 US disclosed
US-20020151715-A1 Imidazole derivatives EVOTEC INTERNATIONAL GMBH (DE) 2002-10-17 US disclosed
WO-2002060877-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-08 WO disclosed
US-4455315-A N-(Difluoromethoxy substituted phenyl)-dichloromaleimides used in agricultural and horticultural fungicidal methods SHOWA DENKO KABUSHIKI KAISHA (JP) 1984-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 CYP3A4 684/4885ALDH1A1 1142/4885MAOB 1169/4885
US-20050004367-A1 Sulfonamide derivatives AR, SULT2A1, SHBG CYP3A4 97/4885ALDH1A1 841/4885MAOB 2371/4885
US-20030191311-A1 A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease GRIN1, GRIN2B, GRIN3B CYP3A4 4439/4885ALDH1A1 3511/4885MAOB 837/4885
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 CYP3A4 4073/4885ALDH1A1 3613/4885MAOB 2910/4885
US-20020151715-A1 Imidazole derivatives GRIN2B, GRIN1, GRIN2A CYP3A4 4242/4885ALDH1A1 3660/4885MAOB 705/4885
US-20100216806-A1 ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER HDAC5, HDAC1, HDAC4 CYP3A4 3549/4885ALDH1A1 1218/4885MAOB 789/4885
US-20030187268-A1 Imidazole derivatives GRIN2B, GRIN1, GRIN2A CYP3A4 4242/4885ALDH1A1 3660/4885MAOB 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.